Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates

GlobeNewswire08-09

Dosing initiated in healthy participants in Phase 1a/b trial for ABI-5366 targeting recurrent genital herpes, with interim Phase 1a first-in-human data expected in Q3 2024 and interim Phase 1b data in...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2458324304?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/by7HdGeYi.U8vLYly8kKRw--~B/aD00NjE7dz0yMjI3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/460d964ae4991b15a5864572dea0f515","is_english":true,"pubTime":"2024-08-09 04:05","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2458324304","market":"us","top_or_hot":-1,"title":"Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates","media":"GlobeNewswire","content":"<div>\n<p>Dosing initiated in healthy participants in Phase 1a/b trial for ABI-5366 targeting recurrent genital herpes, with interim Phase 1a first-in-human data expected in Q3 2024 and interim Phase 1b data in...</p>\n\n<a href=\"https://finance.yahoo.com/news/assembly-biosciences-reports-second-quarter-200500134.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-09 04:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/assembly-biosciences-reports-second-quarter-200500134.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dosing initiated in healthy participants in Phase 1a/b trial for ABI-5366 targeting recurrent genital herpes, with interim Phase 1a first-in-human data expected in Q3 2024 and interim Phase 1b data in...</p>\n\n<a href=\"https://finance.yahoo.com/news/assembly-biosciences-reports-second-quarter-200500134.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HDV","symbol_name":"iShares High Dividend Equity Fun","start_time":0,"source_url":"https://finance.yahoo.com/news/assembly-biosciences-reports-second-quarter-200500134.html","article_id":"2458324304","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/by7HdGeYi.U8vLYly8kKRw--~B/aD00NjE7dz0yMjI3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/460d964ae4991b15a5864572dea0f515"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2458324304","pubTimestamp":1723147500,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Dosing initiated in healthy participants in Phase 1a/b trial for ABI-5366 targeting recurrent genital herpes, with interim Phase 1a first-in-human data expected in Q3 2024 and interim Phase 1b data in participants with recurrent genital herpes expected in first half of 2025. Dosing initiated in Phase 1b trial for ABI-4334 in participants with chronic HBV infection, with interim Phase 1b data expected by end of year. Two additional pipeline candidates, ABI-1179 and ABI-6250, anticipated to enter clinic by end of year. SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024  -- Assembly Biosciences, Inc. , a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results and recent updates for the second quarter ended June 30, 2024.The Phase 1a portion of a Phase 1a/b clinical study of ABI-5366, a long-acting herpes simplex virus  helicase-primase inhibitor candidate; the Phase 1a portion in healthy participants and the Phase 1b portion to b","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"HDV":"iShares High Dividend Equity Fun","ASMB":"Assembly Biosciences Inc.","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4588":"碎股"},"translate_title":"Assembly Biosciences报告2024年第二季度财务业绩和最新更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASMB":1,"HDV":1},"content_text":"Dosing initiated in healthy participants in Phase 1a/b trial for ABI-5366 targeting recurrent genital herpes, with interim Phase 1a first-in-human data expected in Q3 2024 and interim Phase 1b data in participants with recurrent genital herpes expected in first half of 2025\nDosing initiated in Phase 1b trial for ABI-4334 in participants with chronic HBV infection, with interim Phase 1b data expected by end of year\nTwo additional pipeline candidates, ABI-1179 and ABI-6250, anticipated to enter clinic by end of year\n\n SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results and recent updates for the second quarter ended June 30, 2024.\n“Entering the second half of the year, I’m incredibly proud of our team’s accomplishments on our path to delivering novel therapeutics for individuals living with serious viral diseases,” said Jason Okazaki, chief executive officer and president of Assembly Bio. “We are rapidly progressing toward key inflection points for our clinical development programs and remain on track with the data sets we plan to deliver in 2024. Specifically, in the third quarter, we look forward to sharing interim Phase 1a data for ABI-5366 in healthy participants. The pharmacokinetic data in this study will enable us to assess ABI-5366's ability to reach the target concentrations we have established for antiviral efficacy and to support our once-weekly oral dosing profile, while also informing dose selection in the Phase 1b part of the study in participants with recurrent genital herpes.”\nSecond Quarter 2024 and Recent Highlights\n\nFirst participants were dosed in two clinical trials: \n  \nThe Phase 1a portion of a Phase 1a/b clinical study of ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidate; the Phase 1a portion in healthy participants and the Phase 1b portion to be conducted in participants with recurrent genital herpes\nA Phase 1b study of ABI-4334, a next-generation, highly potent capsid assembly modulator candidate, in participants with chronic hepatitis B virus (HBV) infection\n \nScientific conference presentations highlighted: \n  \nPreclinical data for ABI-5366 (poster presentation) and ABI-1179 (poster and oral presentation) featured at the International Herpesvirus Workshop held July 13-17, 2024. ABI-1179 is the long-acting HSV helicase-primase inhibitor candidate contributed by Gilead Sciences, Inc. (Gilead) under the collaboration between Assembly Bio and Gilead\nPreclinical data for ABI-6250, an oral, small molecule HBV/hepatitis delta virus (HDV) entry inhibitor candidate, featured in a poster presentation at the European Association for the Study of the Liver (EASL) Congress™ 2024 held June 5-8, 2024\nPreclinical data for ABI-6250 featured in an oral presentation at the Science of HBV Cure Meeting 2024 held July 26-27, 2024\n \nStrengthened balance sheet with equity investments that resulted in aggregate gross proceeds to Assembly Bio of approximately $12.6 million, supporting advancement of antiviral portfolio and extending cash runway into Q1 2026\n\nUpcoming Anticipated Milestones\n\nABI-5366 Phase 1a interim clinical data in healthy participants expected in Q3 2024 and interim Phase 1b data in participants with recurrent genital herpes expected in the first half of 2025\nABI-4334 Phase 1b interim clinical data expected by the end of 2024\nTwo additional candidates, ABI-1179 and ABI-6250, are anticipated to enter the clinic by the end of 2024\n\nUpcoming Conferences\n\nAbstract highlighting preclinical data for ABI-6250 accepted for poster presentation at the International HBV Meeting taking place September 11-15, 2024, in Chicago\n\nSecond Quarter 2024 Financial Results\n\nCash, cash equivalents and marketable securities were $109.2 million as of June 30, 2024, compared to $113.0 million as of March 31, 2024. Assembly Bio’s cash position is projected to fund operations into Q1 2026.\nRevenue from collaborative research was $8.5 million for the three months ended June 30, 2024. There was no revenue recognized for the same period in 2023. Revenue for the three months ended June 30, 2024, consists of amounts recognized under the collaboration with Gilead.\nResearch and development expenses were $16.3 million for the three months ended June 30, 2024, compared to $12.5 million for the same period in 2023. The increase is attributable to having more candidates in development in 2024.\nGeneral and administrative expenses were $4.5 million for the three months ended June 30, 2024, compared to $5.0 million for the same period in 2023. The decrease is primarily due to a decrease in non-cash stock-based compensation expense.\nNet loss attributable to common stockholders was $11.2 million, or $1.98 per basic and diluted share, for the three months ended June 30, 2024, compared to $16.9 million, or $3.88 per basic and diluted share, for the same period in 2023.\n\nThe investigational products and investigational product candidates referenced here have not been approved anywhere globally, and their safety and efficacy have not been established.\nAbout Assembly BiosciencesAssembly Biosciences is a biotechnology company dedicated to the development of innovative small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Led by an accomplished team of leaders in virologic drug development, Assembly Bio is committed to improving outcomes for patients struggling with the serious, chronic impacts of herpesvirus, hepatitis B virus (HBV) and hepatitis delta virus (HDV) infections. For more information, visit assemblybio.com.\nForward-Looking StatementsThe information in this press release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. These risks and uncertainties include: Assembly Bio’s ability to realize the potential benefits of its collaboration with Gilead Sciences, Inc., including all financial aspects of the collaboration and equity investments; Assembly Bio’s ability to initiate and complete clinical studies involving its therapeutic product candidates, including studies contemplated by Assembly Bio’s collaboration with Gilead, in the currently anticipated timeframes or at all; safety and efficacy data from clinical or nonclinical studies may not warrant further development of Assembly Bio’s product candidates; clinical and nonclinical data presented at conferences may not differentiate Assembly Bio’s product candidates from other companies’ candidates; results of nonclinical studies may not be representative of disease behavior in a clinical setting and may not be predictive of the outcomes of clinical studies; and other risks identified from time to time in Assembly Bio’s reports filed with the U.S. Securities and Exchange Commission (the SEC). You are urged to consider statements that include the words may, will, would, could, should, might, believes, hopes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal or the negative of those words or other comparable words to be uncertain and forward-looking. Assembly Bio intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. More information about Assembly Bio’s risks and uncertainties are more fully detailed under the heading “Risk Factors” in Assembly Bio’s filings with the SEC, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Except as required by law, Assembly Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. \nContacts  Investor and Corporate: Shannon Ryan SVP, Investor Relations, Corporate Affairs and Alliance Management (415) 738-2992 investor_relations@assemblybio.com\nMedia: Sam Brown Inc.Hannah Hurdle(805) 338-4752ASMBMedia@sambrown.com \n\n\n\nASSEMBLY BIOSCIENCES, INC.\n\n\nCONDENSED CONSOLIDATED BALANCE SHEETS\n\n\n(In thousands except for share amounts and par value)\n\n\n \n \n \n \n \n \n\n\n \nJune 30,\n \n \nDecember 31,\n \n\n\n \n2024\n \n \n2023\n \n\n\n \n(Unaudited)\n \n \n \n \n\n\nASSETS\n \n \n \n \n \n\n\nCurrent assets\n \n \n \n \n \n\n\nCash and cash equivalents\n$\n19,208\n \n \n$\n19,841\n \n\n\nMarketable securities\n90,011\n \n \n110,406\n \n\n\nAccounts receivable from collaboration\n—\n \n \n43\n \n\n\nPrepaid expenses and other current assets\n3,712\n \n \n3,497\n \n\n\nTotal current assets\n112,931\n \n \n133,787\n \n\n\n \n \n \n \n \n \n\n\nProperty and equipment, net\n349\n \n \n385\n \n\n\nOperating lease right-of-use assets\n1,731\n \n \n2,339\n \n\n\nOther assets\n312\n \n \n312\n \n\n\nTotal assets\n$\n115,323\n \n \n$\n136,823\n \n\n\n \n \n \n \n \n \n\n\nLIABILITIES AND STOCKHOLDERS' EQUITY\n \n \n \n \n \n\n\nCurrent liabilities\n \n \n \n \n \n\n\nAccounts payable\n$\n801\n \n \n$\n461\n \n\n\nAccrued research and development expenses\n2,531\n \n \n885\n \n\n\nOther accrued expenses\n3,587\n \n \n5,744\n \n\n\nDeferred revenue from a related party - short-term\n33,060\n \n \n30,915\n \n\n\nOperating lease liabilities - short-term\n1,295\n \n \n1,220\n \n\n\nTotal current liabilities\n41,274\n \n \n39,225\n \n\n\n \n \n \n \n \n \n\n\nDeferred revenue from a related party - long-term\n38,916\n \n \n55,379\n \n\n\nOperating lease liabilities - long-term\n451\n \n \n1,122\n \n\n\nTotal liabilities\n80,641\n \n \n95,726\n \n\n\n \n \n \n \n \n \n\n\nCommitments and contingencies\n \n \n \n \n \n\n\n \n \n \n \n \n \n\n\nStockholders' equity\n \n \n \n \n \n\n\nPreferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding\n—\n \n \n—\n \n\n\nCommon stock, $0.001 par value; 150,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 6,345,561 and 5,482,752 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively\n6\n \n \n5\n \n\n\nAdditional paid-in capital\n840,946\n \n \n826,921\n \n\n\nAccumulated other comprehensive loss\n(293\n)\n \n(81\n)\n\n\nAccumulated deficit\n(805,977\n)\n \n(785,748\n)\n\n\nTotal stockholders' equity\n34,682\n \n \n41,097\n \n\n\nTotal liabilities and stockholders' equity\n$\n115,323\n \n \n$\n136,823\n \n\n\n\n\n\n\nASSEMBLY BIOSCIENCES, INC.\n\n\nCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS\n\n\n(In thousands except for share and per share amounts)\n\n\n(Unaudited)\n\n\n \n\n\n \nThree Months Ended June 30,\n \n \nSix Months Ended June 30,\n \n\n\n \n2024\n \n \n2023\n \n \n2024\n \n \n2023\n \n\n\nCollaboration revenue from a related party\n$\n8,533\n \n \n$\n—\n \n \n$\n14,318\n \n \n$\n—\n \n\n\n \n \n \n \n \n \n \n \n \n \n \n \n\n\nOperating expenses\n \n \n \n \n \n \n \n \n \n \n \n\n\nResearch and development\n16,259\n \n \n12,523\n \n \n28,138\n \n \n27,070\n \n\n\nGeneral and administrative\n4,477\n \n \n4,965\n \n \n9,112\n \n \n9,977\n \n\n\nTotal operating expenses\n20,736\n \n \n17,488\n \n \n37,250\n \n \n37,047\n \n\n\nLoss from operations\n(12,203\n)\n \n(17,488\n)\n \n(22,932\n)\n \n(37,047\n)\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n\n\nOther income\n \n \n \n \n \n \n \n \n \n \n \n\n\nInterest and other income, net\n1,457\n \n \n592\n \n \n3,109\n \n \n1,201\n \n\n\nTotal other income\n1,457\n \n \n592\n \n \n3,109\n \n \n1,201\n \n\n\nLoss before income taxes\n(10,746\n)\n \n(16,896\n)\n \n(19,823\n)\n \n(35,846\n)\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n\n\nIncome tax expense\n406\n \n \n—\n \n \n406\n \n \n—\n \n\n\nNet loss\n$\n(11,152\n)\n \n$\n(16,896\n)\n \n$\n(20,229\n)\n \n$\n(35,846\n)\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n\n\nOther comprehensive loss\n \n \n \n \n \n \n \n \n \n \n \n\n\nUnrealized (loss) gain on marketable securities\n(54\n)\n \n188\n \n \n(212\n)\n \n478\n \n\n\nComprehensive loss\n$\n(11,206\n)\n \n$\n(16,708\n)\n \n$\n(20,441\n)\n \n$\n(35,368\n)\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n\n\nNet loss per share, basic and diluted\n$\n(1.98\n)\n \n$\n(3.88\n)\n \n$\n(3.64\n)\n \n$\n(8.33\n)\n\n\nWeighted average common shares outstanding, basic and diluted\n5,642,752\n \n \n4,355,007\n \n \n5,563,033\n \n \n4,303,244","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2458324304"}